TRVI - Trevi Therapeutics  Inc logo

TRVI

Trevi Therapeutics Inc

Rev โ€”top 1%5Y
Hold

Trevi Therapeutics develops Haduvio, an oral therapy for chronic cough linked to idiopathic pulmonary fibrosis and non-IPF interstitial lung disease. The company is conducting clinical trials to assess its efficacy in cough reduction for these conditions.

โš•๏ธ Healthcare NASDAQ Listed 2019 $ USD
$1,000 invested 5 years ago โ†’$8,443today

Score Overview

1 Year
Scoreโ€”
Net Growth-19.52%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-50.58%
Net Trend60%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-96.19%
Net Trend43%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

Trevi Therapeutics Inc fundamental performance

Across Trevi Therapeutics Inc's full reported history, from 2019 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 26M to -$ 42M. Revenue increased in 0% of the years measured; net income in 43%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 17.73โ€”
1 Year2025-08-12
$ 7.33141.88%
5 Years2021-08-12
$ 2.108x
All Time2019-05-07
$ 7.89124.71%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 51M$ 318M
2025$ 0.00-$ 42M$ 188M
2024$ 0.00-$ 47M$ 107M
2023$ 0.00-$ 29M$ 82M
2022$ 0.00-$ 29M$ 120M
2021$ 0.00-$ 33M$ 36M
2020$ 0.00-$ 32M$ 45M
IPO2019$ 0.00-$ 26M$ 57M

Explore beyond TRVI

You're looking at Trevi Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies